{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:01:56Z","timestamp":1791414116672,"version":"4.3.3"},"reference-count":32,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T00:00:00Z","timestamp":1582243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T00:00:00Z","timestamp":1582243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2020,2,21]]},"abstract":"<jats:p>A phase 2 study of gepotidacin demonstrated the safety and efficacy of 3 gepotidacin doses (750\u2009mg every 12 h [q12h], 1,000\u2009mg q12h, and 1,000\u2009mg every 8 h [q8h]) in hospitalized patients with suspected\/confirmed Gram-positive acute bacterial skin and skin structure infections (ABSSSIs). Evaluating microbiology outcomes and responses were secondary endpoints.<\/jats:p>","DOI":"10.1128\/aac.01302-19","type":"journal-article","created":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T13:42:12Z","timestamp":1575985332000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":19,"title":["<i>In Vitro<\/i>\n            Activity and Microbiological Efficacy of Gepotidacin from a Phase 2, Randomized, Multicenter, Dose-Ranging Study in Patients with Acute Bacterial Skin and Skin Structure Infections"],"prefix":"10.1128","volume":"64","author":[{"given":"Nicole E.","family":"Scangarella-Oman","sequence":"first","affiliation":[{"name":"Medicine Opportunities Research Unit, GlaxoSmithKline, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen A.","family":"Ingraham","sequence":"additional","affiliation":[{"name":"Medicine Opportunities Research Unit, GlaxoSmithKline, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney A.","family":"Tiffany","sequence":"additional","affiliation":[{"name":"Medicine Opportunities Research Unit, GlaxoSmithKline, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Tomsho","sequence":"additional","affiliation":[{"name":"Target and Pathway Validation, Target Sciences, GlaxoSmithKline Research and Development, GlaxoSmithKline, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie F.","family":"Van Horn","sequence":"additional","affiliation":[{"name":"Target and Pathway Validation, Target Sciences, GlaxoSmithKline Research and Development, GlaxoSmithKline, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David N.","family":"Mayhew","sequence":"additional","affiliation":[{"name":"Computational Biology, Functional Genomics, GlaxoSmithKline Research and Development, GlaxoSmithKline, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline R.","family":"Perry","sequence":"additional","affiliation":[{"name":"Medicine Opportunities Research Unit, GlaxoSmithKline, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa C.","family":"Ashton","sequence":"additional","affiliation":[{"name":"Medicine Opportunities Research Unit, GlaxoSmithKline, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne F.","family":"Dumont","sequence":"additional","affiliation":[{"name":"Medicine Opportunities Research Unit, GlaxoSmithKline, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzhong","family":"Huang","sequence":"additional","affiliation":[{"name":"Medicine Opportunities Research Unit, GlaxoSmithKline, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Brown","sequence":"additional","affiliation":[{"name":"Computational Biology, Human Genetics, GlaxoSmithKline Research and Development, GlaxoSmithKline, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda A.","family":"Miller","sequence":"additional","affiliation":[{"name":"Medicine Opportunities Research Unit, GlaxoSmithKline, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1177\/2049936117723228"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12235"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-13-252"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-10-151"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir034"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu296"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0038577"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.168.14.1585"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-227X-13-26"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1198-743X(16)30095-7"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.suc.2008.09.006"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0143276"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2012.11.050"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature09197"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02095-16"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(02)00369-9"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.5.2098-2101.2005"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a025320"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00496-08"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00115-16"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01221-18"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy145"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02820-15"},{"key":"e_1_3_3_25_2","volume-title":"Sivextro package insert","author":"Merck & Co., Inc","year":"2017","unstructured":"Merck & Co., Inc. 2017. Sivextro package insert. Merck & Co., Inc, Whitehouse Station, NJ."},{"key":"e_1_3_3_26_2","volume-title":"Dalvance package insert","author":"Allergan USA, Inc","year":"2018","unstructured":"Allergan USA, Inc. 2018. Dalvance package insert. Allergan USA, Inc, Madison, NJ."},{"key":"e_1_3_3_27_2","volume-title":"Orbactiv package insert","author":"Melinta Therapeutics, Inc","year":"2019","unstructured":"Melinta Therapeutics, Inc. 2019. Orbactiv package insert. Melinta Therapeutics, Inc, Lincolnshire, IL."},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.46.8.2498-2506.2002"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btu170"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.38.3.1008-1015.2000"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-0554-6_12"},{"key":"e_1_3_3_32_2","first-page":"164","article-title":"PHYLIP\u2013Phylogeny Inference Package (version 3.2)","volume":"5","author":"Felsenstein J","year":"1989","unstructured":"Felsenstein J. 1989. PHYLIP\u2013Phylogeny Inference Package (version 3.2). Cladistics 5:164\u2013166.","journal-title":"Cladistics"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/molbev\/mst197"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01302-19","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01302-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:48:31Z","timestamp":1645480111000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01302-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,21]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,2,21]]}},"alternative-id":["10.1128\/AAC.01302-19"],"URL":"https:\/\/doi.org\/10.1128\/aac.01302-19","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,21]]},"assertion":[{"value":"2019-08-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01302-19"}}